Crystal Structures of HIV-1 Reverse Transcriptases Mutated at Codons 100, 106 and 108 and Mechanisms of Resistance to Non-nucleoside Inhibitors

Journal of Molecular Biology

Volumn 336, Issue 3, 2004, Pages 569-578

  Ren, J ^a   Nichols, C E ^a   Chamberlain, P P ^a   Weaver, K L ^b   Short, S A ^b   Stammers, D K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

Author keywords

DNA polymerase; Drug resistance mechanism; HIV 1; Reverse transcriptase mutants; X ray crystallography

Indexed keywords

ALANINE; ISOLEUCINE; LEUCINE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TNK 651; TYROSINE; UNCLASSIFIED DRUG; VALINE;

ARTICLE; CODON; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; GENE MUTATION; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0842289678     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2003.12.055     Document Type: Article

References (42)

1. De Clercq E. HIV resistance to reverse transcriptase inhibitors. Biochem. Pharmacol. 47:1994;155-169.
2. Schinazi R.F., Larder B.A., Mellors J.W. Mutations in retroviral genes associated with drug resistance. Int. Antivir. News. 8:2000;65-91.
3. Kohlstaedt L.A., Wang J., Friedman J.M., Rice P.A., Steitz T.A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 256:1992;1783-1790.
4. Ren J., Esnouf R., Garman E., Somers D., Ross C., Kirby I., Keeling J., et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nature Struct. Biol. 2:1995;293-302.
5. Ding J., Das K., Tantillo C., Zhang W., Clark A.D.J., Jessen S., Lu X., et al. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor a-APA R 95845 at 2.8 Å resolution. Structure. 3:1995;365-379.
6. Esnouf R., Ren J., Ross C., Jones Y., Stammers D., Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nature Struct. Biol. 2:1995;303-308.
7. Spence R.A., Kati W.M., Anderson K.S., Johnson K.A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science. 267:1995;988-993.
8. Richman D.D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S.A., Sullivan J., et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1994;1660-1666.
9. Sardana V.V., Emini E.A., Gotlib L., Graham D.J., Lineberger D.W., Long W.J., Wolfgang J.A., et al. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. J. Biol. Chem. 267:1992;17526-17530.
10. Tanaka H., Takashima H., Ubasawa M., Sekiya K., Nitta I., Baba M., Shigeta S., et al. Structure-activity relationships of 1-[(2-hydroxyethoxy) methyl]-6-(phenylthio)thymine analogues: effects of substituents at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity. J. Med. Chem. 35:1992;337-345.
11. Hopkins A.L., Ren J., Esnouf R.M., Willcox B.E., Jones E.Y., Ross C., Miyasaka T., et al. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 39:1996;1589-1600.
12. Young S.D., Britcher S.F., Tran L.O., Payne L.S., Lumma W.C., Lyle T.A., et al. L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 39:1995;2602-2605.
13. Balzarini J., Pelemans H., Aquaro S., Perno C.F., Witvrouw M., Schols D., et al. Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication. Mol. Pharmacol. 50:1996;394-401.
14. Fujiwara T., Sato A., el-Farrash M., Miki S., Abe K., Isaka Y., et al. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 42:1998;1340-1345.
15. Huang H., Chopra R., Verdine G.L., Harrison S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science. 282:1998;1669-1675.
16. Jacobo-Molina A., Ding J.P., Nanni R.G., Clark A.D.J., Lu X., Tantillo C., et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl Acad. Sci. USA. 90:1993;6320-6324.
17. Ren J., Esnouf R.M., Hopkins A.L., Jones E.Y., Kirby I., Keeling J., et al. 3'-azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes. Proc. Natl Acad. Sci. USA. 95:1998;9518-9523.
18. Chamberlain P.P., Ren J., Nichols C.E., Douglas L., Lennerstrand J., Larder B.A., et al. Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215. J. Virol. 76:2002;10015-10019.
19. Das K., Ding J., Hsiou Y., Clark A.D., Moereels H., Koymans L., et al. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. J. Mol. Biol. 264:1996;1085-1100.
20. Ren J., Nichols C., Bird L., Chamberlain P., Weaver K., Short S., et al. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J. Mol. Biol. 312:2001;795-805.
21. Ren J., Milton J., Weaver K.L., Short S.A., Stuart D.I., Stammers D.K. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Struct. Fold. Des. 8:2000;1089-1094.
22. Ren J., Esnouf R.M., Hopkins A.L., Warren J., Balzarini J., Stuart D.I., Stammers D.K. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry. 37:1998;14394-14403.
23. Hsiou Y., Das K., Ding J., Clark A.D., Kleim J.-P., Rosner M., et al. HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. J. Mol. Biol. 284:1998;313-323.
24. Hsiou Y., Ding J., Das K., Clark A.D. Jr, Boyer P.L., Lewi P., et al. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J. Mol. Biol. 309:2001;437-445.
25. Lindberg J., Sigurosson S., Lowgren S., Andersson H.O., Sahlberg C., Noreen R., et al. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur. J. Biochem. 269:2002;1670-1677.
26. Maga G., Amacker M., Ruel N., Hubscher U., Spadari S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. J. Mol. Biol. 274:1997;738-747.
27. Buckheit R.W., Snow M.J., Fliakas-Boltz V., Kinjerski T.L., Russell J.D., Pallansch L.A., et al. Highly potent oxathiin carboxanilide derivatives with efficacy against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus isolates. Antimicrob. Agents. Chemother. 41:1997;831-837.
28. Yang S.S., Pattabiraman N., Gussio R., Pallansch L., Buckheit R.W., Bader J.P. Cross-resistance analysis and molecular modeling of nonnucleoside reverse transcriptase inhibitors targeting drug-resistance mutations in the reverse transcriptase of human immunodeficiency virus. Leukemia. 11:1997;89-92.
29. Buckheit R.W., Kinjerski T.L., Fliakas-Boltz V., Russell J.D., Stup T.L., Pallansch L.A., et al. Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide. Antimicrob. Agents Chemother. 39:1995;2718-2727.
30. Balzarini J., Brouwer W.G., Dao D.C., Osika E.M., De Clercq E. Identification of novel thiocarboxanilide derivatives that suppress a variety of drug-resistant mutant human immunodeficiency virus type 1 strains at a potency similar to that for wild-type virus. Antimicrob. Agents Chemother. 40:1996;1454-1466.
31. Balzarini J., Perez-Perez M.J., Velazquez S., San-Felix A., Camarasa M.J., De Clercq E., Karlsson A. Suppression of the breakthrough of human immunodeficiency virus type 1 (HIV-1) in cell culture by thiocarboxanilide derivatives when used individually or in combination with other HIV-1-specific inhibitors (i.e. TSAO derivatives). Proc. Natl Acad. Sci. USA. 92:1995;5470-5474.
32. Ding J., Das K., Moereels H., Koymans L., Andries K., Janssen P.A.J., et al. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nature Struct. Biol. 2:1995;407-415.
33. Wilson J.E., Wright L.L., Martin J.L., Haire S.E., Ray P.H., Painter G.R., Furman P.A. Recombinant human immunodeficiency virus type 1 reverse transcriptase is heterogeneous. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 11:1996;20-30.
34. Stammers D.K., Somers D.O.N., Ross C.K., Kirby I., Ray P.H., Wilson J.E., et al. Crystals of HIV-1 reverse transcriptase diffracting to 2.2 Å resolution. J. Mol. Biol. 242:1994;586-588.
35. Esnouf R.M., Ren J., Garman E.F., Somers D.O.N., Ross C.K., Jones E.Y., et al. Continuous and discontinuous changes in the unit cell of HIV-1 reverse transcriptase crystals on dehydration. Acta Crystallog. sect. D. 54:1998;938-954.
36. Sakabe N. X-ray diffraction data collection system for modern protein crystallography with a Weissenberg camera and an imaging plate using synchrotron radiation. Nucl. Instrum. Methods Phys. Res. 303:1991;448-463.
37. Stuart D.I., Jones E.Y. Weissenberg data collection for macromolecular crystallography. Curr. Opin. Struct. Biol. 3:1993;737-740.
38. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276:1996;307-326.
39. Brunger A.T., Adams P.D., Clore G.M., Delano W.L., Gros P., Grosse K.R.W., et al. Crystallography system: a new software suite for macromolecular structure determination. Acta Crystallog. sect. D. 54:1998;905-921.
40. Ren J., Esnouf R., Hopkins A., Ross C., Jones Y., Stammers D., Stuart D. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure. 3:1995;915-926.
41. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallog. sect. A. 47:1991;110-119.
42. Stuart D.I., Levine M., Muirhead H., Stammers D.K. The crystal structure of cat pyruvate kinase at a resolution of 2.6 Å J. Mol. Biol. 134:1979;109-142.